Blood neurofilament light levels predict non-relapsing progression following anti-CD20 therapy in relapsing and primary progressive multiple sclerosis: findings from the ocrelizumab randomised, double-blind phase 3 clinical trials
血液中神经丝轻链水平可预测复发型和原发进展型多发性硬化症患者接受抗CD20治疗后的非复发进展：来自奥克瑞珠单抗随机、双盲3期临床试验的结果
期刊:EBioMedicine
影响因子:10.8
doi:10.1016/j.ebiom.2023.104662
Bar-Or, Amit; Thanei, Gian-Andrea; Harp, Christopher; Bernasconi, Corrado; Bonati, Ulrike; Cross, Anne H; Fischer, Saloumeh; Gaetano, Laura; Hauser, Stephen L; Hendricks, Robert; Kappos, Ludwig; Kuhle, Jens; Leppert, David; Model, Fabian; Sauter, Annette; Koendgen, Harold; Jia, Xiaoming; Herman, Ann E
